These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1927130)

  • 1. [Inter- and intra-individual variability of pharmacokinetic parameters for contraceptive steroids].
    Carol W; Klinger G; Jäger R; Kasch R; Michels W
    Zentralbl Gynakol; 1991; 113(13):783-7. PubMed ID: 1927130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of physical training on the pharmacokinetics of steroidal contraceptives].
    Klinger G; Seidel E; Carol W; Boer J; Pocha C
    Zentralbl Gynakol; 1991; 113(22):1240-5. PubMed ID: 1755260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
    Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
    Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of ethinyl estradiol following the administration of combination contraceptive preparations].
    Carol W; Klinger G; Jäger R; Kasch R
    Zentralbl Gynakol; 1990; 112(3):135-41. PubMed ID: 2336888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of contraceptive steroids with reference to long-term administration].
    Carol W; Klinger G; Michels W; Boer J; Pocha C
    Zentralbl Gynakol; 1991; 113(23):1298-303. PubMed ID: 1796663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol.
    Stanczyk FZ; Lobo RA; Chiang ST; Woutersz TB
    Contraception; 1990 Jan; 41(1):39-53. PubMed ID: 2105872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of olestra on systemic levels of oral contraceptives.
    Miller KW; Williams DS; Carter SB; Jones MB; Mishell DR
    Clin Pharmacol Ther; 1990 Jul; 48(1):34-40. PubMed ID: 2196143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
    Roy P; Jakate AS; Patel A; Abramowitz W; Wangsa J; Persiani S; Kapil R
    J Clin Pharmacol; 2005 Mar; 45(3):329-36. PubMed ID: 15703367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
    Joshi JV; Sankolli GM; Shah RS; Joshi UM
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):192-5. PubMed ID: 3086241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
    Ragueneau-Majlessi I; Levy RH; Janik F
    Epilepsia; 2002 Jul; 43(7):697-702. PubMed ID: 12102671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
    Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR
    Clin Pharmacol Ther; 1998 Dec; 64(6):597-602. PubMed ID: 9871424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observations with Anteovin in relation to age.
    Szigethy A
    Ther Hung; 1991; 39(1):11-5. PubMed ID: 1858069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
    Scheffler MR; Colburn W; Kook KA; Thomas SD
    Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):668-74. PubMed ID: 17190377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the estrogen-progesterone combination preparations gravistat and Minisiston on carbohydrate metabolism].
    Albus C; Männchen E
    Zentralbl Gynakol; 1987; 109(8):521-6. PubMed ID: 3111130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dermatologic complications of oral hormonal contraception (Gravistat)].
    Mikrut W
    Wiad Lek; 1986 Nov; 39(21):1462-5. PubMed ID: 3577158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.